Clinical Trial Update: A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc) [Phase 1]

View source ↗

Summary

A Phase 1 study of TAK-007 in adults with refractory lupus nephritis or refractory systemic sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Sclerosis

Drugs mentioned

• TAK-007

Snippet

Sponsor: Takeda | Conditions: Refractory Lupus Nephritis, Refractory Systemic Sclerosis | Phase 1 | Status: WITHDRAWN